Research Communication

The Nodal Standard Uptake Value (SUV) as a Prognostic Factor in Head and Neck Squamous Cell Cancer

Umut Demirci1*, Ugur Coskun2, U Ozgur Akdemir3, Mustafa Benekli2, Ozlem Kapucu3, Secil Ozkan4, Tansel Cakir3, Meltem Baykara5, Suleyman Buyukberber2

Abstract

Background/Aims: The aim of present study is to evaluate the predictive and prognostic role of high [18F] fluoro-D-glucose (FDG) uptake of primary tumor and nodal metastasis in squamous cell carcinoma of head and neck (HNSCC). Methodology and Patients: Between February 2006 and July 2010, we retrospectively evaluated 64 patients with primary HNSCC in an institutional imaging trial. All patients who underwent evaluation pretreatment FDG-positron emission tomography/computed tomography (FDG-PET/CT) imaging and 33 (51%) had pre- and after treatment FDG-PET/CT imaging. All treatments were performed with curative intent. Abnormal FDG uptakes were analyzed using maximum standardized uptake values (SUVm). The disease-free survival (DFS) and overall survival (OS) were evaluated with several prognostic factors such as pre-treatment SUVm and % change in SUVm. Results: Tumor sites are nasopharynx (n= 29, 45.3%), larynx (n= 16, 25%), oropharynx (n= 13, 20.4%) and hypopharynx (n= 6, 9.4%). Median age was 58 (range: 16-87) and most patients (84.4%) had stage III/IV lesions. Objective response rate was 78.2 %. The median primary tumor SUVm was 13.4 (range, 4.8–33.1), median nodal SUVm was 4.45 (range, 0–25.6) and median % change in SUVm was 74.1 (range, -61-100). On multivariate analysis, nodal SUVm and surgery remained significant predictors of DFS. There was no statistical significance found between survival and other factors. Conclusions: We have found that while nodal SUVm is prognostic for DFS, primary tumor SUVm and % change in SUVm are not.

Keywords: Head and neck SCC - [18F]fluoro-D-glucose POT/CT - standardized uptake value

Introduction

Head and neck cancer is the eighth most common cause of cancer death (Jemal et al., 2010). Over 60% of HNSCC patients present with locally advanced disease and have a 25% of forming distant metastases. Multimodal treatment with surgery, radiotherapy (RT), chemotherapeutic and targeted agents with multidisciplinary approaches has been used in patients with HNSCC (Pignon et al., 2009). The current approach of HNSCC patients have been induction chemotherapy and/or concurrent chemoradiotherapy (CCRT), thus it is ensuring to preserve organ and organ function. After definitive therapy, patients with locally advanced HNSCC may recur at the locoregional or distant relapse. The most important prognostic factor identified is the stage of the disease. However, we are needed in the additional prognostic factors that can predict treatment outcome. The therapy must be carefully individualized that are improved tumor control and survival (Monerrat et al., 2002; Forastiere et al., 2003; Urba et al., 2006; Pignon et al., 2009).

2-deoxy-2[18F] fluoro-D-glucose- positron emission tomography/computed tomography (FDG-PET/CT) is a physiological imaging technique. FDG-PET/CT has been used in the initial diagnosis, staging, and detection of recurrence in HNSCC. FDG-PET/CT has a higher sensitivity than conventional imaging methods to detect stage of disease accurately. Thus, the role of FDG-PET/CT is increasing in our clinical practice.

The maximum standard uptake of value (SUVm), a semi-quantitative measurement of tumor FDG uptake and enhanced uptake of FDG has been related to aggressive behaviour and less favorable results in many different tumor types such as lung and esophageal cancer (Swisher et al., 2004; Kee et al., 2010). Moreover, SUVm may be related with clinicopathologic features of the tumor in HNSCC. Pretreatment FDG uptake may also have evaluated as a prognostic and predictor factor with HNSCC. We aimed the prognostic utility of measuring FDG uptake in HNSCC prior to treatment with our retrospective experience.

1Department of Medical Oncology, Ataturk Education and Research Hospital, 2Department of Medical Oncology, 3Department of Nuclear Medicine, 4Department of Public Health, Gazı University Faculty of Medicine, Ankara, Turkey *For correspondence: drumutdemirci@gmail.com
Umut Demirci et al

Materials and Methods

Patients

Between February 2004 and July 2010, 64 patients who were diagnosed HNSCC underwent pretreatment FDG-PET/CT at the Department of Medical Oncology, Gazi University Hospital. FDG-uptake was assessed the SUVm. All patients who underwent evaluation also underwent systematic staging after direct laryngoscopy and tissue biopsy diagnosis with chest radiograph, serum chemistry, a contrast-enhanced computed tomography (CT) or magnetic resonans imaging (MRI), and FDG-PET/CT imaging of the head and neck. Patients with distant metastases were not included in this series. We used the Tumor- node- metastasis (TNM) classification of the AJCC (7th edt) (Edge et al., 2010). Thirtythree (51%) of them had pre- and after treatment FDG-PET/CT imaging. At the each visit, routine clinical examination and blood chemistry were performed.

All treatment was performed with curative intent and consisted of definitive RT with or without chemotherapy or definitive resection with or without adjuvant RT. After completion of treatment, patients underwent routine surveillance every three months. All patients gave informed consents for each examination and treatment.

18F-FDG PET/CT Imaging

Whole body FDG-PET/CT data were acquired 60 minutes following the administration of FDG-PET/CT (0.10 mCi/kg of body weight) using a Discovery ST PET-CT scanner (GE Medical Systems, Milwaukee, Wisconsin, USA). Patients had fasted for at least 6 hours and their blood glucose levels were controlled before 18F-FDG injection. All of the patients had blood glucose levels lower than 160 mg/dl. No intravenous contrast material was used for the CT scans. During the uptake phase of 18F-FDG patients laid still in a warm room. Each patient underwent a low dose (120 kV, 10-90 mA) whole body CT scan and subsequently a 3D whole body PET scan with an acquisition time of three minutes per bed position. The resulting axial, coronal and sagittal slices were visually evaluated by two nuclear medicine physicians experienced in whole body FDG-PET/CT imaging.

Quantitative Analysis of 18F-FDG PET-CT Data

Metabolic activities of any lesion with a visually abnormal FDG uptake (uptake greater than its surrounding soft tissues) were analyzed using standardized uptake values (SUV). SUV is a commonly applied semi-quantitative parameter to express tumor FDG uptake. It is calculated by normalizing the radioactivity concentration in tissue for patient weight and injected radioactivity. In order to minimize partial volume effects maximum SUV (SUVmax) was preferred over mean SUV. SUVmax was calculated separately for the primary lesion and each abnormal lymph node. For nodal disease, the highest SUVmax was used for subsequent correlation with clinical outcomes.

Statistics

All statistical analyses were performed using SPSS version 16.0 (SPSS, Chicago, IL). The significances of differences between two categories were established using Mann-Whitney U testing. We dichotomized the clinical features for subsequent univariate and regression analysis. Also the therapeutic effects were evaluated by pre-treatment SUVm and % change in SUV. We calculated the percent change in SUV (%change SUV) as follows: 100x (pre-treatment SUVm - posttreatment SUVm)/ pre-treatment SUVm. Because of the limited number of disease events, we specifically chose to create a Cox regression analysis of DFS and OS hazard ratios.

Results

All patients (n=64) who underwent evaluation pretreatment FDG-PET/CT imaging and 34 had pre- and after treatment FDG-PET/CT imaging. Median age was 58 (range: 16-87) in total 64 patients, 13 women (20.3%), 51 man (79.7%). Tumor sites are nasopharynx (n= 29, 45.3%), larynx (n= 16, 25%), oropharynx (n= 13, 20.4%) and hipopharynx (n= 6, 9.4%). Most patients (54 of 64) (84.4%) had stage III/IV, the remaining 10 patients (15.6%) had stage I/II disease. Forty-four patients (68.8%) had T3,4 disease.

Sixty patients were scheduled to receive definitive RT. Fityseven patients were treated CCRT (69.9 to 70.0 Gy), 40 were concurrent with cisplatin-docetaxel, 17 were cisplatin. While three with early-stage disease were treated only radiotherapy at doses of 60.0 to 70.0 Gy, four patients were not treated RT. Surgery (definitive resection with or without neck dissection) were performed in 15 patients (23.4%).

Induction chemotherapy (TCF; docetaxel- cisplatin-5FU) was performed in four patients with advanced primary tumor (T4) because of constrict to radiation field. After CCRT, three cycles of different regimen (cisplatin-docetaxel or TCF) in were performed like adjuvant intend in locally advanced NPC. All patients were eligible analysis in this study. Objective response rate was 78.2% [38 complete response (CR), 12 partial response (PR)]. One patient had stable disease. Thirteen patients (20.3%) were progressed (PD).

The median primary SUVm in our series was 13.35 (range, 4.8–33.1). The median nodal SUVm in our series was 4.45 (range, 0–25.6). Median % change in SUVm was 74.09 (range, -61–100). Primary tumor SUVm was associated with T stage (p= 0.048), but not stage of disease (p= 0.465). Nodal SUVm was no associated with either T stage (p= 0.525) or stage of disease (p= 0.340).

As shown in Table 1, in univariate analysis there was no correlation between DFS and study parameters that are

| Table 1. Univariate Log-rank Testing of Clinical Features for DFS and OS (Mann Whitney U) |
|------------------------------------------|-------------|-------------|
| DFS | OS |
| Primary SUVm <13.45/>13.45 | 0.861 | 0.152 |
| Nodal SUVm <4.45 >/=4.45 | 0.067 | 0.686 |
| Stage I-II /III-IV | 0.12 | 0.014 |
| T stage I-II /III-IV | 0.037 | 0.003 |
| Surgery No/Yes | 0.037 | 0.651 |
| Age 60<60> | 0.07 | 0.6 |
| Sex Man/ woman | 0.125 | 0.953 |
Discussion

FDG-PET/CT has been shown to be an effective imaging method for staging work-up (Kresnik et al., 2001; Murakami et al., 2007) also treatment was altered in 31% of patients with HNSCC by FDG-PET/CT (Fleming et al., 2007). Recent studies showed that a correlation with FDG uptake and biologic features of tumors such as proliferation, hypoxia and poor clinical outcomes in HNSCC (Couture et al., 2002; Burgman et al., 2001; Bos et al., 2002).

Current study involved a remarkable number of previously untreated HNSCC patients with treated different combination of treatment modality, either surgery followed by adjuvant RT and/or chemotherapy, induction chemotherapy, curative RT or CCRT, and salvage surgery. We have investigated that FDG uptake in patients with HNSCC is correlated with prediction (tumor response) and prognosis (survival). Also nearly half of patients had pre and post FDG-PET/CT imaging. Advanced tumors (T3-4) and stage (stage III/IV) generally tend to have higher SUVm (Halfpenny et al., 2002; Allal et al., 2004). We showed that primary tumor SUVm was associated with T stage. Recent studies found that a pretreatment primary tumor SUVm of 5.5 to 12.0 or greater predicted inferior response to treatment, local disease control, and poor survival outcome in patients with HNSCC, including both surgical and non-surgical series (Minn et al., 1997; Halfpenny et al., 2002; Allal et al., 2004; Kim et al., 2008; Inokuchi et al., 2011). In contrast with these previous studies, we showed that primary tumor SUVm and % change in SUVm were not prognostic or predictive. Similar our findings, there was no role for pretreatment SUVm as a predictor of CCRT outcome in HNSCC in recent retrospective and prospective studies (Schinagl et al., 2011; Roh et al., 2007).

However nodal SUVm correlated with DFS. Nodal SUVm may be used to select patients for intensive treatments. In a recent retrospective study, Yao et al. (2009) examined 177 patients who had FDG PET scans before treatment. Most frequently most patients had locally advanced tumors and a median pre-treatment primary SUVm of 10.65 (range: 2.6-48.2) and a median pre-treatment nodal SUVm of 7.33 (range: 1.5-33.1). Primary SUVm was found to be significantly associated with DFS and OS. Nodal SUVm was significantly associated with distant metastasis.

In a study showed that a significant difference was found between the recurrent and non-recurrent cases regarding the post-treatment SUVm (<3 vs >3) and the % change in SUVm (<60 vs >60) the overall accuracy was 88.2% (45/51). They concluded that analysis of the post-treatment SUVm and the % change in SUVm were useful to predict the prognosis after CCRT (Hoshikawa et al., 2009). However we did not find similar association with between % change in SUVm and survival.

We suggested that nodal SUVm is correlated with poorer outcome thus these patients should have more aggressive treatment combinations. FDG-PET/CT was evaluated for individualized therapy in HNSCC with two recent studies. Roh et al (2007) showed that SUVm was an independent prognostic factor for survival. They concluded that primary surgery followed by adjuvant RT and chemotherapy prolonged survival than by primary organ preservation strategy with CCRT in high SUVm. In Sang Yoon Kim et al study (2008), local disease control and survival outcomes were generally higher in the surgery group than those in the RT group, and this difference was significant in patients with a high (6.0) tumor SUVm but not in those with a low (<6.0) tumor SUVm. They
concluded that patients with high tumor FDG uptake may have improved survival with early surgical intervention followed by RT. Primary RT or CRT may be optional only in patients with low FDG uptake who hope to avoid surgery and postoperative morbidity.

The disadvantage of present study is a retrospective study, there may be potential biases especially in different tumor site and treatment combinations, those can affect association SUVm and treatment outcomes.

High SUVm is associated with a controversial results in previous studies however our results suggest that pretreatment nodal FDG uptake correlated with treatment outcome in patients with HNSCC. We need to be determined by further prospective research that a potential role for FDG-PET/CT as guidance for the primary treatment modality of patients with HNSCC who undergo more homogeneous study design.

References


